SELLAS Life Sciences (SLS) Shares Outstanding (Diluted Average) (2012 - 2026)

SELLAS Life Sciences (SLS) has 12 years of Shares Outstanding (Diluted Average) data on file, last reported at $172.5 million in Q1 2026.

• Shares Outstanding (Diluted Average) for Q1 2026 came in at $172.5 million, up 96.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $172.5 million (up 96.54% YoY), and the FY2025 annual result was $109.1 million, up 78.18% from the prior year.
• Shares Outstanding (Diluted Average) advanced to $172.5 million in Q1 2026 per SLS's latest filing, from $109.1 million in the prior quarter.
• Over five years, Shares Outstanding (Diluted Average) peaked at $172.5 million in Q1 2026 and troughed at $15.9 million in Q1 2022.
• A 5-year average of $57.0 million and a median of $44.8 million in 2024 frame the typical range for Shares Outstanding (Diluted Average).
• The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Diluted Average) rose 6.86% in 2022, then soared 121.99% in 2024.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $19.4 million in 2022, then jumped by 43.21% to $27.8 million in 2023, then surged by 120.33% to $61.2 million in 2024, then surged by 78.18% to $109.1 million in 2025, then soared by 58.17% to $172.5 million in 2026.
• Business Quant data shows SLS's Shares Outstanding (Diluted Average) at $172.5 million in Q1 2026, $109.1 million in Q4 2025, and $98.3 million in Q3 2025.